FAS抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using FAS mouse mAb against Hela (1), Jurkat (2) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using FAS mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using FAS mouse mAb (green) and negative control (red).    

  
  

FAS antibodies target the FAS receptor (CD95/APO-1), a cell surface protein belonging to the tumor necrosis factor (TNF) receptor superfamily. The FAS/FAS ligand (FASL) system plays a critical role in regulating apoptosis, immune homeostasis, and immune tolerance. Upon binding to FASL, FAS initiates extrinsic apoptosis through the formation of the death-inducing signaling complex (DISC), activating caspases that execute programmed cell death. This pathway is essential for eliminating autoreactive lymphocytes, maintaining peripheral tolerance, and controlling cytotoxic T cell responses.

FAS antibodies are broadly categorized into agonist or antagonist types. Agonist antibodies mimic FASL, inducing apoptosis in FAS-expressing cells, and are explored in cancer immunotherapy to trigger tumor cell death. Antagonist antibodies block FAS/FASL interaction, potentially mitigating pathological apoptosis in conditions like autoimmune diseases or neurodegenerative disorders. Dysregulation of FAS signaling is implicated in diseases such as autoimmune lymphoproliferative syndrome (ALPS), where defective FAS-mediated apoptosis leads to lymphadenopathy and autoimmunity.

Research tools like monoclonal FAS antibodies are widely used to study apoptotic mechanisms, immune cell interactions, and disease models. However, therapeutic applications face challenges, including hepatotoxicity from systemic FAS activation and the complexity of balancing pro- and anti-apoptotic signals. Despite these hurdles, FAS antibodies remain pivotal in both basic research and clinical exploration for modulating apoptosis-related pathologies.